Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
AKTIENPREIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionPrudential Financial Inc
Latest Disclosed Ownership2,956 shares
Latest Disclosed Value $ 978,052
Prudential Financial Inc reports 77.79% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 13, 2026 - Prudential Financial Inc filed a 13F-HR form disclosing ownership of 2,956 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $844,529 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 13,309 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -77.79% during the quarter. The current value of the position is $744,321 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,956 -10,353 -77.79 978 -81.50 0.0012
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,309 4,177 45.74 5,287 26.97 0.0064
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,132 -74,790 -89.12 4,164 -84.78 0.0049
2025-08-12 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 83,922 -88,084 -51.21 27,366 -41.08 0.0354
2025-05-13 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 172,006 153,253 817.22 46,445 952.70 0.0662
2025-02-11 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,753 -64,212 -77.40 4,413 -80.66 0.0060
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 82,965 79,306 2,167.42 22,818 2,466.59 0.0321
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,659 -202 -5.23 889 54.07 0.0013
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,861 -305 -7.32 577 -27.60 0.0008
2024-02-13 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,166 254 6.49 797 15.17 0.0012
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,912 13 0.33 693 -6.49 0.0011
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,899 405 11.59 741 43.13 0.0011
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,494 -1,085 -23.70 518 -52.48 0.0008
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,579 -7,902 -63.31 1,088 -58.36 0.0018
2022-11-04 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,481 7,623 156.92 2,613 269.59 0.0044
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,858 -74 -1.50 707 -12.17 0.0011
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,932 -60 -1.20 805 -11.05 0.0011
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,992 1,040 26.32 905 20.19 0.0011
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,952 -155 -3.77 753 8.03 0.0011
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,107 -27 -0.65 697 19.35 0.0010
2021-05-12 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,134 -2,122 -33.92 584 -28.26 0.0009
2021-08-16 2020-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 0129 02043Q107 6,256 6,185 8,711.27 814 8,040.00 0.0014
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,256 6,185 814 0.0014
2021-08-05 2020-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 71 0 0.00 10 -9.09 0.0014
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,249 6,178 910 0.0017
2021-08-05 2020-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 0148 02043Q107 71 -8 -10.13 11 22.22 0.0020
2020-08-12 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,984 16,905 2,516 0.0048
2021-08-05 2020-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 0108 02043Q107 79 -4,995 -98.44 9 -98.46 0.0023
2020-05-12 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,474 14,400 2,120 0.0047
2020-02-11 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,074 -300 -5.58 584 35.19 0.0009
2019-11-13 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,374 -82,300 -93.87 432 -93.21 0.0007
2019-08-08 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 87,674 87,634 219,085.00 6,362 158,950.00 0.0099
2021-08-05 2019-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 40 -88,904 -99.96 4 -99.94 0.0017
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 82,874 -6,070 7,745 0.0129
2019-02-07 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 88,944 15,500 21.10 6,274 -2.38 0.0110
2018-11-07 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 73,444 38,500 110.18 6,427 86.78 0.0095
2018-08-13 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 34,944 30,200 636.59 3,441 509.03 0.0051
2018-05-04 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,744 40 0.85 565 -5.52 0.0009
2018-02-13 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,704 200 4.44 598 13.04 0.0008
2017-11-02 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,504 100 2.27 529 50.71 0.0009
2017-08-07 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,404 200 4.76 351 63.26 0.0005
2017-05-10 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,204 4,204 215 0.0003
2017-02-07 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -4,674 -100.00 0 -100.00
2016-11-04 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,674 0 0.00 317 22.39 0.0005
2016-08-09 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,674 330 7.60 259 -5.13 0.0004
2016-05-09 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,344 -18,900 -81.31 273 -87.52 0.0005
2016-02-12 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,244 -20,300 -46.62 2,188 -37.47 0.0040
2015-11-10 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,544 -2,480 -5.39 3,499 -36.58 0.0069
2015-08-06 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 46,024 -6,740 -12.77 5,517 0.13 0.0098
2015-05-01 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 52,764 -2,180 -3.97 5,510 3.38 0.0095
2015-02-06 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 54,944 -16,900 -23.52 5,330 -5.01 0.0097
2014-11-12 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 71,844 -32,170 -30.93 5,611 -14.61 0.0106
2014-08-13 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 104,014 -14,878 -12.51 6,571 -17.68 0.0116
2014-05-14 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 118,892 -9,800 -7.62 7,982 -3.59 0.0149
2014-02-11 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 128,692 -37,700 -22.66 8,279 -22.27 0.0164
2013-11-07 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 166,392 -3,400 -2.00 10,651 102.30 0.0226
2013-08-07 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 169,792 169,792 5,265 0.0117
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.